AOD-9604 fat loss: what the human trials actually showed

Key takeaways

• AOD-9604 is a synthetic fragment of human growth hormone (Tyr-hGH177-191, the C-terminal lipolytic region plus an added tyrosine), developed by the Australian biotech Metabolic Pharmaceuticals as an obesity drug. It was never approved .
• In rodents the fragment is a real lipolytic. It cut body weight and fat mass and raised beta3-adrenergic receptor levels in obese mice , and across the human trials it did not raise IGF-1 or cause the insulin resistance that full-length growth hormone does .
• Six randomized, double-blind, placebo-controlled human trials were run. The two efficacy studies were a 12-week study in 300 obese adults and a larger 24-week study that randomized about 500 .
• The larger, longer trial did not reproduce the weight loss seen in the earlier studies. The developer wound the obesity program down in the mid-2000s and never brought AOD-9604 to approval .
• AOD-9604 later received self-affirmed GRAS status as a US food ingredient, up to 1 mg per person per day . A food-ingredient clearance is not a drug approval, and WADA prohibits it in sport .

What AOD-9604 is, and where it came from

AOD-9604 stands for anti-obesity drug 9604. It is a synthetic version of residues 177 through 191 of human growth hormone, the C-terminal stretch that biochemistry work in the 1990s tied to the fat-burning activity of the whole hormone, with an extra tyrosine added at the N-terminal end to stabilize the peptide. It came out of Monash University (F.M. Ng and colleagues) and was licensed to Metabolic Pharmaceuticals, an Australian biotech that carried it through preclinical work and into human trials for obesity .

The rationale was clean on paper. Full-length growth hormone can shift fat, but it also drives up blood sugar, insulin resistance, and IGF-1, which makes it a poor obesity drug. The C-terminal fragment kept the fat-cell activity in lab assays without those liabilities, and across the human trials AOD-9604 did not raise IGF-1 or provoke insulin resistance . The open question was always whether that selectivity produced real weight loss in a person, not just lipolysis in a dish.

What the rodent studies actually showed

In diet-induced obese mice, AOD-9604 reduced body weight and fat mass and raised the repressed levels of beta3-adrenergic receptor RNA in white fat. The picture is not purely beta3-driven, though: in beta3-receptor knockout mice, long-term treatment failed to change body weight, yet an acute experiment still increased energy expenditure and fat oxidation in those same knockouts. So the lipolytic effect does not depend strictly on direct beta3 signaling. This body of work reproduced across independent groups, and it is the mechanism story AOD-9604 still carries in vendor copy .

In people, the larger trial did not beat placebo

Six randomized, double-blind, placebo-controlled trials were run in humans. The human-trial record is thin and mostly lives in two safety papers written by people tied to the developer's own program, so read the numbers as the company's account, not an independent one. The two efficacy studies were a 12-week study in 300 obese adults on oral doses from 1 to 30 mg, then a larger 24-week study across 16 Australian centers that enrolled 534 and randomized about 500 .

The result that matters is simple. A weight-loss effect showed up in the earlier trials but not in the last, larger study once an intensive diet-and-exercise program was built into it . Tolerability was never the problem; the peptide behaved close to placebo on safety. It just did not deliver enough weight loss to justify an obesity drug, and Metabolic Pharmaceuticals wound the program down in the mid-2000s without ever reaching approval .

• Well tolerated. Across the six placebo-controlled trials the safety profile tracked placebo, with no IGF-1 rise and no insulin resistance .
• Not effective enough. The larger, longer trial did not reproduce the early weight-loss signal against placebo .
• Never approved. No AOD-9604 obesity drug cleared any regulator; it circulates as a research-vial peptide and a nominated compounding bulk substance .
• The modern comparator is brutal. AOD-9604 was a mid-2000s candidate; today's approved GLP-1 drugs (semaglutide, tirzepatide) produce far larger weight loss, so the bar it missed then sits much higher now.

Why the rodent effect did not carry to people

The likeliest reason for the gap is that the rodent assays measured one biochemical step, beta-adrenergic lipolysis in fat cells, while human weight loss needs a coordinated multi-tissue response: central appetite control, satiety hormones, hepatic energy balance, and behavior. AOD-9604 may push lipolysis in fat without touching the central appetite circuits the GLP-1 class engages. Moving fat out of adipocytes is not the same as moving the scale.

Pharmacokinetics did not help. AOD-9604 has a short circulating half-life, and the human dosing schedules did not sustain fat-tissue exposure at the concentrations the in vitro work used. On top of that, a 12-to-24-week absolute-weight endpoint is noisy and sensitive to diet and adherence, so a small pharmacological signal gets buried unless the effect size is large. It was not.

GRAS, gray market, and anti-doping status in 2026

AOD-9604 stayed in circulation as a research-vial peptide after the obesity program lapsed. There is no approved AOD-9604 drug, and the FDA's interim policy on bulk substances for compounding covers nominated research peptides like this one . A community-sourced vial does not carry the identity, purity, dose accuracy, or sterility of the investigational supply used in the trials. If you are going to run it anyway, the numbers that protect you are your reconstitution math and a current third-party assay from your source, because nothing about a gray-market vial is guaranteed by the published program.

AOD-9604 did get a self-affirmed 'Generally Recognized As Safe' (GRAS) determination in the US in 2014, for use in foods, drinks, and dietary supplements up to 1 mg per person per day, conditional on publishing its pre-existing safety data . That clears a safety bar for a tiny dietary amount. It says nothing about whether the peptide causes weight loss, and it is not an FDA drug approval. Reading GRAS as 'FDA-approved for fat loss' gets both halves wrong.

For athletes there is a harder line: WADA prohibits AOD-9604 in sport, treating it as a non-approved substance because no government anywhere has approved it for human therapeutic use . That is the same fact the drug record shows, viewed from the anti-doping side.

The honest read for 2026

AOD-9604's reputation rests on a real but narrow rodent literature and on the credibility an Australian biotech program lent it years ago. The staying power in the vial market did the rest. The published human evidence does not show meaningful fat loss. The obesity field has since moved through tirzepatide, retatrutide, the higher-dose Wegovy program, and the CagriSema combination, so the standard any fat-loss peptide has to meet now is far above where AOD-9604 landed.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 7 entries, primary canon (PubMed, FDA, WADA) plus the developer-linked peer-reviewed human-trial and safety papers and one science trade report, acknowledged inline, last reviewed 2026-07-08.

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.